ATE310517T1 - CABERGOLINE AND PRAMIPEXOLE FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES, PARTICULARLY PARKINSON'S DISEASE - Google Patents
CABERGOLINE AND PRAMIPEXOLE FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES, PARTICULARLY PARKINSON'S DISEASEInfo
- Publication number
- ATE310517T1 ATE310517T1 AT99919772T AT99919772T ATE310517T1 AT E310517 T1 ATE310517 T1 AT E310517T1 AT 99919772 T AT99919772 T AT 99919772T AT 99919772 T AT99919772 T AT 99919772T AT E310517 T1 ATE310517 T1 AT E310517T1
- Authority
- AT
- Austria
- Prior art keywords
- cabergoline
- pramipexole
- treatment
- disease
- nervous system
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title abstract 5
- 229960004596 cabergoline Drugs 0.000 title abstract 5
- 229960003089 pramipexole Drugs 0.000 title abstract 5
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 4
- 208000018737 Parkinson disease Diseases 0.000 title abstract 3
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- 238000011284 combination treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8561998P | 1998-05-15 | 1998-05-15 | |
| US8794398P | 1998-06-04 | 1998-06-04 | |
| PCT/US1999/007024 WO1999059563A2 (en) | 1998-05-15 | 1999-05-07 | Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE310517T1 true ATE310517T1 (en) | 2005-12-15 |
Family
ID=26772918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99919772T ATE310517T1 (en) | 1998-05-15 | 1999-05-07 | CABERGOLINE AND PRAMIPEXOLE FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES, PARTICULARLY PARKINSON'S DISEASE |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6503920B1 (en) |
| EP (1) | EP1076559B1 (en) |
| JP (1) | JP2002515425A (en) |
| KR (3) | KR20060056416A (en) |
| CN (1) | CN1301159A (en) |
| AT (1) | ATE310517T1 (en) |
| AU (1) | AU748629B2 (en) |
| BR (1) | BR9909917A (en) |
| CA (1) | CA2327299A1 (en) |
| DE (1) | DE69928521T2 (en) |
| DK (1) | DK1076559T3 (en) |
| EA (4) | EA004474B1 (en) |
| ES (1) | ES2251191T3 (en) |
| HU (1) | HUP0101803A3 (en) |
| IL (1) | IL139682A0 (en) |
| NO (1) | NO20005757D0 (en) |
| NZ (2) | NZ526071A (en) |
| PL (1) | PL344574A1 (en) |
| SG (1) | SG121745A1 (en) |
| SK (1) | SK16272000A3 (en) |
| TR (1) | TR200003356T2 (en) |
| WO (1) | WO1999059563A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| DE10053397A1 (en) * | 2000-10-20 | 2002-05-02 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
| DE10043321B4 (en) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition |
| DE10064453A1 (en) * | 2000-12-16 | 2002-07-04 | Schering Ag | Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases |
| DE10138275A1 (en) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Connections to eliminate anhedonia |
| DE10148233A1 (en) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Compounds to reduce excessive food intake |
| MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| GB0221513D0 (en) | 2002-09-17 | 2002-10-23 | Generics Uk Ltd | Novel compounds and processes |
| NZ553587A (en) | 2004-08-13 | 2010-12-24 | Boehringer Ingelheim Int | Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof |
| EA201001086A1 (en) | 2004-08-13 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | THE COMPOSITION OF PELLETS OF THE PROLONGED SURVENT, CONTAINING PRAMIPEXOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, THE WAY OF ITS MANUFACTURE AND ITS APPLICATION |
| CA2641665A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
| PL232974B1 (en) * | 2015-12-09 | 2019-08-30 | Ofta Spolka Z Ograniczona Odpowiedzialnoscia | Application of the dopaminergic receptors type 2 agonists in treatment of eye chronic diseases caused by the increased level of endothelium derivative cell growth factor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| DE3937271A1 (en) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | TRANSDERMAL APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE |
| JPH08502759A (en) * | 1993-08-18 | 1996-03-26 | アルコン ラボラトリーズ，インコーポレイテッド | Use of ergoline derivatives for the treatment of glaucoma |
| US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
| FR2728374A1 (en) * | 1994-12-15 | 1996-06-21 | Aerospatiale | METHOD AND APPARATUS FOR PROVIDING INFORMATION, ALERT, OR ALARM FOR AN AIRCRAFT NEAR THE GROUND |
| US5650420A (en) * | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
-
1999
- 1999-05-07 HU HU0101803A patent/HUP0101803A3/en unknown
- 1999-05-07 EA EA200001192A patent/EA004474B1/en not_active IP Right Cessation
- 1999-05-07 EP EP99919772A patent/EP1076559B1/en not_active Expired - Lifetime
- 1999-05-07 US US09/674,838 patent/US6503920B1/en not_active Expired - Fee Related
- 1999-05-07 CA CA002327299A patent/CA2327299A1/en not_active Abandoned
- 1999-05-07 EA EA200300125A patent/EA200300125A1/en unknown
- 1999-05-07 KR KR1020067007719A patent/KR20060056416A/en not_active Ceased
- 1999-05-07 NZ NZ526071A patent/NZ526071A/en unknown
- 1999-05-07 JP JP2000549228A patent/JP2002515425A/en active Pending
- 1999-05-07 ES ES99919772T patent/ES2251191T3/en not_active Expired - Lifetime
- 1999-05-07 SK SK1627-2000A patent/SK16272000A3/en unknown
- 1999-05-07 DK DK99919772T patent/DK1076559T3/en active
- 1999-05-07 EA EA200300124A patent/EA200300124A1/en unknown
- 1999-05-07 AU AU37419/99A patent/AU748629B2/en not_active Ceased
- 1999-05-07 KR KR1020067007720A patent/KR20060056417A/en not_active Ceased
- 1999-05-07 KR KR1020007012760A patent/KR20010043612A/en not_active Ceased
- 1999-05-07 TR TR2000/03356T patent/TR200003356T2/en unknown
- 1999-05-07 WO PCT/US1999/007024 patent/WO1999059563A2/en not_active Ceased
- 1999-05-07 NZ NZ508184A patent/NZ508184A/en unknown
- 1999-05-07 SG SG200206791A patent/SG121745A1/en unknown
- 1999-05-07 CN CN99805219A patent/CN1301159A/en active Pending
- 1999-05-07 EA EA200200955A patent/EA200200955A1/en unknown
- 1999-05-07 AT AT99919772T patent/ATE310517T1/en not_active IP Right Cessation
- 1999-05-07 DE DE69928521T patent/DE69928521T2/en not_active Expired - Fee Related
- 1999-05-07 PL PL99344574A patent/PL344574A1/en not_active IP Right Cessation
- 1999-05-07 IL IL13968299A patent/IL139682A0/en unknown
- 1999-05-07 BR BR9909917-9A patent/BR9909917A/en not_active Application Discontinuation
-
2000
- 2000-11-14 NO NO20005757A patent/NO20005757D0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE144420T1 (en) | USE OF RILUZOLE TO TREAT PARKINSON'S AND PARKINSON'S SYNDROMES | |
| ATE241365T1 (en) | PREPARATIONS CONTAINING SACCHARIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES | |
| DE60236413D1 (en) | INHIBITORS OF HMGB1 FOR THE TREATMENT OF TISSUE DISEASES | |
| WO2002002518A3 (en) | Compounds to treat alzheimer's disease | |
| WO2002002520A3 (en) | Compounds to treat alzheimer's disease | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| DK1632483T3 (en) | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| ATE410506T1 (en) | TREATMENT OF POMPES DISEASE | |
| DE69928521D1 (en) | CABERGOLIN AND PRAMIPEXOL FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM, IN PARTICULAR PARKINSON'S DISEASE | |
| DE60312736D1 (en) | 1,2,4-TRIAMINOBENZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| FR2777781B1 (en) | RILUZOLE AND L-DOPA ASSOCIATIONS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| SE0102147D0 (en) | New methods | |
| DK1392676T3 (en) | Novel heterocyclic urea derivatives and their use as dopamine -D3 - receptor ligands | |
| MY124071A (en) | Treatment of viral disease in swine | |
| ATE384133T1 (en) | RETINOLIC ACID RECEPTOR BETA-2 AND GENE THERAPY VECTORS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| RU2147218C1 (en) | Method of vibration disease treatment | |
| HUP9701606A2 (en) | Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psychointellectual disorders | |
| DE69421705D1 (en) | Use of Efaroxan and its derivatives for the manufacture of a medicament for the treatment of neurogenerative diseases | |
| DE3865283D1 (en) | BUTYLHYDROXYANISOLE FOR TREATING RETROVIRUS DISEASES. | |
| PT1304107E (en) | USE OF OXAZOLIDININ DERIVATIVES FOR THE TREATMENT OF PSORIASIS | |
| ATE288263T1 (en) | USE OF N-OLEOYLETHANOLAMINE TO TREAT PSORIAS (PSORIASIS) | |
| BR0015486A (en) | Neurophylline ligands for treating eye conditions | |
| EA199800737A1 (en) | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF SPECIFICATIONS | |
| UA42274A (en) | METHOD OF PREVENTION AND TREATMENT OF FUNCTIONAL DISORDERS OF THE PATIENT'S ORGANISM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1076559 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |